VERGLEICH VON CO-TRIMAZIN (TRIGLOBE®) UND CO-TRIMOXAZOL BEI HARNWEGSINFEKTIONEN. ERGEBNISSE EINER MULTICENTER-STUDIE

Translated title of the contribution: Comparison of co-trimazine and co-trimoxazole in urinary tract infections

E. W. Rugendorff, Claus Roehrborn, W. Sietzen

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

In a double-blind randomized clinical trial co-trimazine was compared with co-trimoxazole in 212 patients with urinary tract infections. Co-trimazine (TMP 180 mg plus SMZ 820 mg) was given once daily and co-trimoxazole (TMP 160 mg plus SMZ 800 mg) twice daily. 14 to 21 days after the end of treatment the bacteriological cure rate was 90% for co-trimazine and 87% for co-trimoxazole. Bacterial resistance was only observed in a few cases. Side-effects occurred in 11.7% of the patients treated with co-trimazine and in 15.4% of those treated with co-trimoxazole. The side-effects were generally mild and only once in each regimen was treatment discontinued.

Translated title of the contributionComparison of co-trimazine and co-trimoxazole in urinary tract infections
Original languageGerman
Pages (from-to)6596-6603
Number of pages8
JournalTherapiewoche
Volume34
Issue number46
StatePublished - Jan 1 1984

ASJC Scopus subject areas

  • Pharmacology

Fingerprint

Dive into the research topics of 'Comparison of co-trimazine and co-trimoxazole in urinary tract infections'. Together they form a unique fingerprint.

Cite this